1. Home
  2. UCAR vs PMCB Comparison

UCAR vs PMCB Comparison

Compare UCAR & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U Power Limited

UCAR

U Power Limited

N/A

Current Price

$1.58

Market Cap

9.2M

ML Signal

N/A

Logo PharmaCyte  Biotech Inc.

PMCB

PharmaCyte Biotech Inc.

HOLD

Current Price

$0.94

Market Cap

8.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UCAR
PMCB
Founded
2013
1996
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.2M
8.4M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
UCAR
PMCB
Price
$1.58
$0.94
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$5.00
N/A
AVG Volume (30 Days)
14.8K
386.6K
Earning Date
10-13-2025
03-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,816,075.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
57.22
N/A
52 Week Low
$1.40
$0.63
52 Week High
$8.08
$1.90

Technical Indicators

Market Signals
Indicator
UCAR
PMCB
Relative Strength Index (RSI) 46.71 57.10
Support Level $1.46 $0.84
Resistance Level $1.60 $1.00
Average True Range (ATR) 0.08 0.09
MACD 0.02 0.01
Stochastic Oscillator 72.92 75.90

Price Performance

Historical Comparison
UCAR
PMCB

About UCAR U Power Limited

U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.

About PMCB PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Share on Social Networks: